NEO | Comprehensive - Solid Tumor is now PanTracer Tissue. Learn about our PanTracer Portfolio
Powerful, simple solutions for therapy selection
The PanTracer portfolio empowers oncologists with actionable genomic insights for confident, real-time treatment decisions. Whether you’re selecting approved targeted therapies or exploring clinical trials, working from a liquid or tissue biopsy, PanTracer ensures that you’re equipped with the insights you need.
PanTracer Tissue, the next evolution of Neo Comprehensive - Solid Tumor, offers a tissue-based CGP approach, providing deep insights into tumor genome from solid-tumor biopsy samples, helping oncologists make precise, actionable therapy decisions.
PanTracer Tissue + HRD is a single, advanced assay designed specifically for advanced ovarian cancer, uniquely combining Comprehensive Genomic Profiling (CGP) and HRD assessment in one streamlined solution.
 | Broad, guideline-compliant CGP panels |
 | Rapid turnaround time |
 | Actionable and informative reports |
 | Minimal specimen requirements |
In oncology, every decision matters. PanTracer Tissue offers broad, tissue-based CGP designed to support oncologists in delivering personalized care. Aligned with clinical guidelines, this test covers key biomarkers recommended for therapy selection and additional genomic insights for clinical trial enrollment.
Available June 23rd
In the evolving landscape of precision oncology, accessing tumor-specific genomic insights quickly and noninvasively is critical. PanTracer LBx is a liquid biopsy test that delivers comprehensive, clinically actionable insights from a simple blood draw. It empowers real-time decision-making, especially for patients for whom tissue biopsies are not feasible.
COMING SOON
PanTracer Tissue + HRD offers CGP with integrated HRD assessment. Our advanced HRD score assesses BRCA1/2 and tumor genomic instability (GIS), including loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST), to guide personalized treatment decisions.
With real-time molecular insights, PanTracer Tissue + HRD supports more informed, precise, and effective treatment strategies across the ovarian cancer care continuum.
COMING SOON
